Home » Stocks » ABMD

Abiomed, Inc. (ABMD)

Stock Price: $265.25 USD -2.96 (-1.10%)
Updated December 2, 4:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 11.99B
Revenue (ttm) 802.86M
Net Income (ttm) 207.82M
Shares Out 45.10M
EPS (ttm) 4.55
PE Ratio 58.30
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 2
Last Price $265.25
Previous Close $268.21
Change ($) -2.96
Change (%) -1.10%
Day's Open 268.22
Day's Range 263.76 - 268.22
Day's Volume 169,002
52-Week Range 130.51 - 317.00

More Stats

Market Cap 11.99B
Enterprise Value 11.45B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 45.10M
Float n/a
EPS (basic) 4.60
EPS (diluted) 4.55
FCF / Share 5.46
Dividend n/a
Dividend Yield n/a
Earnings Yield 1.72%
FCF Yield 2.05%
Payout Ratio n/a
Shares Short 2.05M
Short Ratio 6.78
Short % of Float n/a
Beta 1.43
PE Ratio 58.30
Forward PE n/a
P/FCF Ratio 48.72
PS Ratio 14.93
PB Ratio 10.39
Revenue 802.86M
Operating Income 223.71M
Net Income 207.82M
Free Cash Flow 246.05M
Net Cash 533.08M
Net Cash / Share 11.80
Gross Margin 85.89%
Operating Margin 27.86%
Profit Margin 25.90%
FCF Margin 30.65%
ROA 11.49%
ROE 19.12%
ROIC 30.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (9)

Buy 4
Overweight 0
Hold 4
Underweight 0
Sell 1

Analyst Consensus: Overweight

Price Target

(17.78% upside)
Current: $265.25
Target: 312.40
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth9.29%29.59%33.34%35.13%43.09%25.41%16.14%25.12%24.94%-
Gross Profit69064049537527919014612710279.17
Operating Income24922515790.1465.1028.678.3616.541.52-11.19
Net Income20325911252.1238.151147.3515.011.50-11.76
Shares Outstanding45.1844.9144.1543.2442.2040.6339.3339.1138.3737.17
Earnings Per Share4.435.612.451.170.852.650.180.370.04-0.32
EPS Growth-21.03%128.98%109.4%37.65%-67.92%1372.22%-51.35%825%--
Operating Cash Flow31525219311576.8043.2923.4726.403.631.57
Capital Expenditures-44.01-44.00-55.86-50.42-15.62-5.19-2.76-2.84-1.75-1.80
Free Cash Flow27120813764.7061.1738.1020.7123.561.89-0.23
Cash & Equivalents44349236223021213276.5876.7177.2260.31
Total Debt---16.34------
Net Cash / Debt44349236221421213276.5876.7177.2260.31
Book Value1,065937690452369292168137126105
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Abiomed, Inc.
Country United States
Employees 1,536
CEO Michael Minogue

Stock Information

Ticker Symbol ABMD
Stock Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Unique Identifier NASDAQ: ABMD
IPO Date July 29, 1987


Abiomed engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; and Impella Connect, a cloud-based technology that enables secure, cloud-based, and remote viewing of the Automated Impella Controller for physicians and hospital staffs. In addition, the company engages in the development of Impella XR Sheath, a sheath designed to expand and recoil to all for ease of use upon insertion of an Impella heart pump and minimize the size of the arteriotomy; Impella BTR, a percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump that is designed for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Asia. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.